FDA briefing documents: Sofosbuvir safe, effective

Share this article:

Gilead's sofosbuvir hep. C drug is safe and effective when used in combination with other therapies. That pronouncement, reported by Reuters today, is not likely to shock anyone, although FDA briefing documents posted on the agency's site ahead of an advisory panel meeting Friday may offer some hints at what reviewers will focus on.

As the news service notes, Gilead is seeking approval to market the drug, sans interferon (INF) but with existing treatment ribavirin (RBV), for patients with the genotype 2 and genotype 3 variants of the diasease. Gilead will also seek approval for use of the drug, with RBV and INF, for patients with the more common genotype 1 variant, as well as for 4, 5 and 6.

Sofosbuvir is vying to become the basis for the first approved all-oral drug for hep. C. Analysts have modeled peak worldwide sales of between $4 billion and $7 billion a year. All-oral regimens are also being tested by BMS and AbbVie.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.

Study says statins not enough for diabetic hearts

Researchers using an experimental test have discovered that the 50% of surveyed diabetics may also have undetected heart muscle damage.